Explore

Trendline Trendline
Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus
Trendline Trendline
FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for Malignant Fungating Wounds at AACR 2026
Trendline Trendline
Pharmaceutical R Pipeline Experiences First Decline in Decades, Citeline Reports

Pharmaceutical R Pipeline Experiences First Decline in Decades, Citeline Reports

Pharmaceutical R Pipeline Experiences First Decline in Decades, Citeline Reports
Trendline Trendline
IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors
Trendline Trendline
Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds

Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds

Vyome to Present Phase 2 Data on VT-1953 for Malignant Fungating Wounds
Trendline Trendline
API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development

API's Lean Derisking Strategy Aims to Streamline Drug Development
Trendline Trendline
API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'
Trendline Trendline
Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights
Trendline Trendline
Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment
Trendline Trendline
Gilead Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Extends Tender Offer for Arcellx Amid Biotech M Challenges
Trendline Trendline
Eli Lilly's Foundayo Pill Approved by FDA, Offers New Weight Loss Option

Eli Lilly's Foundayo Pill Approved by FDA, Offers New Weight Loss Option

Eli Lilly's Foundayo Pill Approved by FDA, Offers New Weight Loss Option